Nova Eye Medical (OTCMKTS:ELXMF – Get Free Report) and Sanara MedTech (NASDAQ:SMTI – Get Free Report) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, risk, valuation and dividends.
Profitability
This table compares Nova Eye Medical and Sanara MedTech’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Nova Eye Medical | N/A | N/A | N/A |
| Sanara MedTech | -31.23% | -3.19% | -0.56% |
Analyst Ratings
This is a summary of current recommendations for Nova Eye Medical and Sanara MedTech, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Nova Eye Medical | 0 | 0 | 0 | 0 | 0.00 |
| Sanara MedTech | 1 | 4 | 0 | 0 | 1.80 |
Valuation and Earnings
This table compares Nova Eye Medical and Sanara MedTech”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Nova Eye Medical | N/A | N/A | N/A | $0.01 | 1.96 |
| Sanara MedTech | $103.12 million | 3.04 | -$37.56 million | ($3.77) | -9.08 |
Nova Eye Medical has higher earnings, but lower revenue than Sanara MedTech. Sanara MedTech is trading at a lower price-to-earnings ratio than Nova Eye Medical, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
12.4% of Nova Eye Medical shares are owned by institutional investors. Comparatively, 8.1% of Sanara MedTech shares are owned by institutional investors. 42.0% of Sanara MedTech shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Summary
Nova Eye Medical beats Sanara MedTech on 6 of the 10 factors compared between the two stocks.
About Nova Eye Medical
Nova Eye Medical Limited designs, develops, manufactures, markets, and sells surgical devices for the treatment of glaucoma in Australia, the United States, Europe, the Asia Pacific, and internationally. It offers iTrack, a glaucoma surgical device to reduce intraocular pressure in adult patients with open-angle glaucoma; iTrack Advance, a canaloplasty microcatheter; Molteno3, a glaucoma drainage device to treat patients with severe or complex glaucoma; and 2RT, a proprietary laser technology to treat patients in early/intermediate age-related macular degeneration. The company was formerly known as Ellex Medical Lasers Limited and changed its name to Nova Eye Medical Limited in July 2020. Nova Eye Medical Limited was incorporated in 1970 and is headquartered in Kent Town, Australia.
About Sanara MedTech
Sanara MedTech Inc., a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns; and HYCOL, a medical hydrolysate of Type I bovine collagen intended for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers. It also provides BIAKOS Antimicrobial Skin and Wound Cleanser, a patented product that contains synergistic ingredients that have been shown to impact mature biofilm microbes; BIAKOS Antimicrobial Wound Gel, an antimicrobial hydrogel wound dressing that helps against planktonic microbes, as well as immature and mature biofilms; and BIAKOS Antimicrobial Skin and Wound Irrigation Solution. In addition, it develops BIASURGE, a no-rinse surgical solution used for wound irrigation; FORTIFY TRG, a freeze-dried, multi-layer small intestinal submucosa extracellular matrix sheet; FORTIFY FLOWABLE extracellular matrix, an advanced wound care device; TEXAGEN, a multi-layer amniotic membrane allograft used as an anatomical barrier with robust handling that can be sutured for securement; and VIM Amnion Matrix, a homologous wound covering product. Sanara MedTech Inc. was incorporated in 2001 and is based in Fort Worth, Texas.
Receive News & Ratings for Nova Eye Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nova Eye Medical and related companies with MarketBeat.com's FREE daily email newsletter.
